News

Analyzing Xerox Holdings' Upcoming Earnings Report Insights

Analyzing Xerox Holdings' Upcoming Earnings Report Insights

Xerox Holdings' Upcoming Earnings Report Overview

Xerox Holdings (XRX) is gearing up to release its latest quarterly earnings report soon. This report is highly anticipated, as investors are eager to find out if the company can exceed expectations and provide positive guidance for the following quarter.

Analysts predict that Xerox Holdings will report an earnings per share (EPS) of $0.54. For both seasoned and new investors, understanding the implications of earnings guidance is essential, as it often drives stock price movements.

Review of Past Performance

Analyzing Previous Earnings Results

Reflecting on the previous earnings release, the company missed the EPS estimate by $0.14, yet the share price rallied by 1.94% in the next trading session.

Xerox Holdings Stock Trends

As of October 25, shares of Xerox Holdings are trading at $9.95. The stock has witnessed a decline of 18.46% over the past year. Given these negative returns, it appears that long-term investors may adopt a bearish stance ahead of the upcoming earnings report.

Analyst Insights on Xerox Holdings

Market Sentiment and Analyst Ratings

Understanding the current market sentiments regarding Xerox Holdings is vital for informed investment decisions. Analysts have assigned a consensus rating of Neutral to the company, based on two ratings. The average one-year price target is about $11.00, implying a potential upside of approximately 10.55% from the current price.

Comparative Ratings Against Peers

To evaluate Xerox Holdings' performance, it helps to compare with peers like Diebold Nixdorf and Corsair Gaming. Here’s a brief analysis:

  • Diebold Nixdorf has received an Outperform rating from analysts, with a robust average 1-year price target of $55.00, indicating an impressive potential upside of 452.76%.
  • Corsair Gaming has a Neutral outlook, with a moderate potential upside of 5.53% and an average 1-year price target of $10.50.

Peer Analysis in the Market

Key Metrics of Competitors

When we analyze the performance of Xerox Holdings alongside Diebold Nixdorf and Corsair Gaming, we can assess their market positions:

Xerox Holdings is positioned with a Neutral consensus rating, exhibiting revenue growth of -10.03%, generating gross profits of $520 million, and achieving a Return on Equity of 0.63%. In comparison, Diebold Nixdorf is trending towards Outperform with a revenue growth of 1.90% and a Return on Equity of 1.48%, while Corsair Gaming shows a steeper revenue decline of -19.71% with an ROE of -4.53%.

Understanding Financial Health

A thorough look into Xerox Holdings reveals its strengths and weaknesses. The company has a commendable net margin of 0.95%, indicating good cost management.

Exploring Xerox Holdings' Business Model

Xerox Holdings Corp specializes in original equipment manufacturing and software solutions, primarily operating in the development and sale of printing technologies. With about 60% of its revenues from the U.S. and the remaining 40% from international markets, the company focuses on large enterprises, producing multifunction printers that are essential in business environments. Beyond equipment sales, Xerox also engages in post-sale services, enhancing the efficiency of print operations with managed print services. They are making strides to expand into digital packaging solutions and printed electronics, diversifying their portfolio.

Financial Analysis and Performance Metrics

Market Capitalization and Growth Challenges

Xerox Holdings shows a lower market capitalization compared to industry averages, reflecting its smaller scale within the sector. Revenue growth has been challenging, with a reported decline of approximately -10.03% recently, which is considerably below the sector's average.

Performance Indicators to Monitor

The company stands out with competitive measures such as a net margin of 0.95%, suggesting effective cost controls. However, its Return on Equity of 0.63% remains below industry norms, hinting at difficulties in optimally utilizing equity. Conversely, its Return on Assets at 0.15% shows effective asset management.

Frequently Asked Questions

What are the key expectations for Xerox Holdings' earnings report?

Analysts anticipate an EPS of $0.54 with a focus on the company's guidance for future performance.

How did Xerox Holdings perform in its last earnings report?

The company missed the EPS estimate by $0.14 but saw a share price increase of 1.94% afterward.

What is the current stock price of Xerox Holdings?

As of October 25, the stock was priced at $9.95, reflecting an overall decline over the past year.

What are analysts' ratings for Xerox Holdings?

The consensus rating is Neutral, with a projected price target of $11.00, indicating potential growth.

How does Xerox compare to its industry peers?

Xerox Holdings ranks well in Gross Profit but lacks in Revenue Growth, compared to peers like Diebold Nixdorf and Corsair Gaming.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 26

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 21

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Crypto Developments: Circle's Blockchain, Ethereum Bets, and More

Updated Category News Views 251

The Current Landscape of Cryptocurrency The last week in the world of cryptocurrency and finance has been nothing less than exhilarating. With significant developments, including the launch of a new blockchain by Circle Internet Group Inc. and major investments in Ethereum, there is plenty to discuss. Let’s explore the most noteworthy stories that are shaping the crypto...

Continue Reading
ezPaycheck 2025 Payroll Software: Cost-Effective Compliance Solution

Updated Category News Views 132

ezPaycheck 2025: The Efficient Payroll Solution The new ezPaycheck 2025 payroll software is now available, offering businesses an excellent in-house solution for payroll processing that is both compliant and economical. This updated version comes with essential features designed to make payroll management easier than ever. Priced at just $169 for a single installation,...

Continue Reading
Investors of Applied Therapeutics, Inc. Should Take Action Now

Updated Category News Views 188

Understanding the Securities Fraud Allegations Against Applied Therapeutics Applied Therapeutics, Inc. (APLT) has found itself at the heart of a securities fraud class action lawsuit. This legal proceeding has been announced by The Law Offices of Frank R. Cruz as they represent investors who acquired shares during a significant time frame. The legal challenge highlights...

Continue Reading
Ardagh Metal Packaging Reports Positive Year-End 2024 Results

Updated Category News Views 148

Ardagh Metal Packaging's Year-End 2024 Results Ardagh Metal Packaging S.A. (NYSE: AMBP) recently reported their impressive results for the full year and fourth quarter of 2024. The company's performance is a reflection of strategic growth and resilience in a challenging market environment. Quarterly and Annual Performance Overview For the fourth quarter of 2024, Ardagh...

Continue Reading
Empowering Voices: The Call to Protect Our Children

Updated Category News Views 243

Making a Stand Against Child Trafficking In a heartfelt initiative, ThinkCareBelieve has announced a powerful call to action aimed at ensuring the safety and protection of children across the nation. This initiative addresses the urgent concern of child trafficking and the plight of missing children, many of whom have been smuggled through borders and placed in unsafe...

Continue Reading